Presentation is loading. Please wait.

Presentation is loading. Please wait.

Malignancy-related events over time for all-bari-RA analysis set (IR).

Published byRudolf Hodge Modified over 5 years ago

Similar presentations

Presentation on theme: "Malignancy-related events over time for all-bari-RA analysis set (IR)."— Presentation transcript:

1 Malignancy-related events over time for all-bari-RA analysis set (IR).
Malignancy-related events over time for all-bari-RA analysis set (IR). A. Cumulative incidence rate of malignancy (excluding NMSC) by time period for all-bari-RA patients (IR per 100 PY; 95% CI). B. Cumulative incidence rate of NMSC by time period of report for all-bari-RA patients (IR per 100 PY; 95% CI). RA: rheumatoid arthritis; IR: incidence rate; NMSC: nonmelanoma skin cancer; PY: patient-years. Josef S. Smolen et al. J Rheumatol 2019;46:7-18 ©2019 by The Journal of Rheumatology

Download ppt "Malignancy-related events over time for all-bari-RA analysis set (IR)."

Similar presentations

Lenalidomide and Dexamethasone (LEN plus DEX) Treatment in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (pts) and Risk of Second Primary Malignancies.

Lenalidomide and Dexamethasone (LEN plus DEX) Treatment in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (pts) and Risk of Second Primary Malignancies.
Time to Distant Metastases (ITT) Cumulative incidence of distant metastases (ITT) Adapted from Jones et al. SABCS 2008, abstract 15. 486826/477169/465253/454771/4406110/4146.

Time to Distant Metastases (ITT) Cumulative incidence of distant metastases (ITT) Adapted from Jones et al. SABCS 2008, abstract /477169/465253/454771/ /4146.
© Cancer Research UK 2008 Registered charity number 1089464 Incidence – UK February 2008.

© Cancer Research UK 2008 Registered charity number Incidence – UK February 2008.
1 Journal Club Alcohol, Other Drugs, and Health: Current Evidence January–February 2014.

1 Journal Club Alcohol, Other Drugs, and Health: Current Evidence January–February 2014.
Module 1 Prof. Hassan Bassiouny, MD Prof. Of Rheumatology, Al-Azhar University Cairo, Egypt RHUHQ12PM028 Date of preparation: January 2012 Targeting the.

Module 1 Prof. Hassan Bassiouny, MD Prof. Of Rheumatology, Al-Azhar University Cairo, Egypt RHUHQ12PM028 Date of preparation: January 2012 Targeting the.
The Risk of Cancer Following Total Hip or Knee Arthroplasty by Ravi Tharani, Frederick J. Dorey, and Thomas P. Schmalzried J Bone Joint Surg Am Volume.

The Risk of Cancer Following Total Hip or Knee Arthroplasty by Ravi Tharani, Frederick J. Dorey, and Thomas P. Schmalzried J Bone Joint Surg Am Volume.
Summary of TB cases across indications and trial periods

Summary of TB cases across indications and trial periods
Algorithm based on the 2016 European League Against Rheumatism (EULAR) recommendations on rheumatoid arthritis (RA) management. Algorithm based on the.

Algorithm based on the 2016 European League Against Rheumatism (EULAR) recommendations on rheumatoid arthritis (RA) management. Algorithm based on the.
Figure 1 Rheumatoid arthritis development over time in relation to the level of inflammation Figure 1 | Rheumatoid arthritis development over time in relation.

Figure 1 Rheumatoid arthritis development over time in relation to the level of inflammation Figure 1 | Rheumatoid arthritis development over time in relation.
Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum
A Critical Evaluation of Clinical Research Study Designs

A Critical Evaluation of Clinical Research Study Designs
Pre (a) and post (b) contrast agent short-axis images of the third metatarsophalangeal (MTP) joint demonstrating intact capsule and plantar plate (arrows).

Pre (a) and post (b) contrast agent short-axis images of the third metatarsophalangeal (MTP) joint demonstrating intact capsule and plantar plate (arrows).
Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum
Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data  Bruce Strober, MD,

Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data  Bruce Strober, MD,
Mean change in patient-reported outcomes from baseline to Week 25 with biweekly or monthly pegloticase compared with placebo. Mean change in patient-reported.

Mean change in patient-reported outcomes from baseline to Week 25 with biweekly or monthly pegloticase compared with placebo. Mean change in patient-reported.
Patient disposition during open-label longterm exposure period.

Patient disposition during open-label longterm exposure period.
Benefit-risk balance. Benefit-risk balance. Predicted probabilities of developing serious infection versus predicted probabilities of achieving Boolean-based.

Benefit-risk balance. Benefit-risk balance. Predicted probabilities of developing serious infection versus predicted probabilities of achieving Boolean-based.
Percentage of patients achieving minimal disease activity (MDA): A

Percentage of patients achieving minimal disease activity (MDA): A
ACR20, ACR50, and ACR70 response rates during the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo. ACR20,

ACR20, ACR50, and ACR70 response rates during the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo. ACR20,
Clinical relevance of thrombocytosis in primary care: a prospective cohort study of cancer incidence using English electronic medical records and cancer.

Clinical relevance of thrombocytosis in primary care: a prospective cohort study of cancer incidence using English electronic medical records and cancer.

Similar presentations

Ads by Google